{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028748","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.260237+00:00","generated_at":"2026-06-22T03:07:21.893849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InfuSystem reports record Q3 revenue $27.3M; net income turns positive; FY guidance at low end","bullets":["Record Q3 net revenue $27.3M (+3% YoY); ITS segment revenue record $17.4M (+5% YoY).","Net income $0.4M ($0.02/diluted) vs net loss $0.4M in prior-year quarter; operating income up $1.3M to $0.9M.","Gross margin improved 200 bps to 59.5%; ITS gross margin 65.6%, DME 48.7%.","FY2022 guidance: revenue ~$112M (low end of prior 10-13% growth); Adj. EBITDA ~$22M (19-20% margin).","Nov 3: formed wound therapy partnership with Sanara MedTech and signed distribution agreement with Cork Medical."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028748","json":"https://secwatch.observer/filing/0001628280-22-028748.json","markdown":"https://secwatch.observer/filing/0001628280-22-028748.md","text":"https://secwatch.observer/filing/0001628280-22-028748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/0001628280-22-028748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/infu-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:07:21.893849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b5b3468d120c90a07dd8b0cd44bb8acb2719d6b","claim":"InfuSystem Holdings, Inc reported the third quarter ended September 30, 2022 results: revenue $27.3 million, net income $0.4 million, EPS $0.02 per diluted share.","evidence_excerpt":"• Net revenues totaled $27.3 million, an increase of 3% vs. prior year. ◦ Integrated Therapy Services (\"ITS\") net revenue was $17.4 million, an increase of 5% vs. prior year. ◦ Durable Medical Equipment Services (\"DME Services\") net revenue was $9.9 million, a decrease of 1% vs. prior year. • Gross profit was $16.2 million, an increase of 6% vs. prior year. • Gross margin was 59.5%, an increase of 2.0% vs. prior year. ◦ ITS gross margin was 65.6%, an increase of 1.8% vs. prior year. ◦ DME Services gross margin was 48.7%, an increase of 1.7% vs. prior year. • Operating income increased $1.3 million to $0.9 million vs. prior year. • Net income of $0.4 million, or $0.02 per diluted share, an increase of $0.9 million vs. prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/0001628280-22-028748-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$27.3 million"},{"label":"Net income","value":"$0.4 million"},{"label":"EPS","value":"$0.02 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}